King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Fahad Z. Alsharif
Dr. Fahad Z. Alsharif is a Consultant Haematologist specialising in adult haematological malignancies, chronic myeloid leukaemia, and bone marrow transplantation outcomes — a trusted general haematology specialist in Riyadh, Saudi Arabia providing evidence-based care to international patients. He is a co-editor of the 4th edition (2015) of the Guidelines for Management of Haematological Malignancies at his institution, a widely referenced regional resource.
- Consultant Haematologist specialising in adult haematological malignancies
- Co-editor — Guidelines for Management of Haematological Malignancies, 4th Edition (2015)
- Published contributor to proteomics-based tyrosine kinase inhibitor research in chronic myeloid leukaemia
- Co-author on international research into CD20 expression in acute lymphoblastic leukaemia
- Author/co-author on multiple adult bone marrow transplantation outcome studies
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Internal Medicine Residency
Fellowships & Special Training
- Fellowship in Adult Haematology
- Advanced Training in Haematological Malignancies and Bone Marrow Transplantation
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Registered Consultant
- American Society of Hematology (ASH) — Member
- Saudi Society of Haematology — Member
Areas of Expertise
Major Conditions Treated
- Chronic Myeloid Leukaemia (CML)
- Acute Lymphoblastic Leukaemia (ALL)
- Acute Myeloid Leukaemia (AML)
- Multiple Myeloma
- Lymphoma (Hodgkin and Non-Hodgkin)
- Myelodysplastic Syndrome (MDS)
- Plasma Cell Leukaemia
- Bone Marrow Failure Syndromes
- Post-Transplant Complications
Sub-specialties
- Chronic Myeloid Leukaemia & TKI Therapy: Tyrosine kinase inhibitor selection, resistance testing, and proteomics-guided management of CML — a general haematology specialist in Riyadh providing precision care for international patients.
- Adult Haematological Malignancies: Evidence-based chemotherapy, targeted therapy, and transplantation pathways for acute leukaemia, lymphoma, myeloma, and MDS.
- Guideline Development & Clinical Governance: Co-editor of institutional guidelines for the management of haematological malignancies (4th Edition, 2015).
Advanced Procedures & Treatments
- Tyrosine Kinase Inhibitor Therapy (Imatinib, Dasatinib, Nilotinib, Ponatinib)
- Induction and Consolidation Chemotherapy for Acute Leukaemia
- Rituximab and CD20-Directed Therapy
- Proteasome Inhibitors and Immunomodulatory Drugs (Myeloma)
- Consolidative Stem Cell Transplantation Referral
- Minimal Residual Disease Monitoring
- Flow Cytometry and Molecular Diagnostics
- Supportive and Transfusion Medicine
Professional Experience
Current Affiliation
- Consultant Haematologist, General Haematology Section — King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia (Present)
Past Affiliations
- Fellowship training in Adult Haematology — completed prior to KFSHRC consultancy
Academic & Research Roles
- Co-Editor — Guidelines for Management of Haematological Malignancies, 4th Edition (KFSHRC Riyadh, 2015)
- Clinical faculty — KFSHRC Haematology training programmes
- Contributing author — multiple peer-reviewed haematology publications
Key Achievements
- Co-editor of a widely referenced regional guideline on management of haematological malignancies (2015)
- Contributing author to proteomics-based tyrosine kinase inhibitor research in CML (2014)
- Co-author on research covering CD20 expression in adult ALL
- Author/co-author on multiple adult BMT outcome studies
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- Saudi Society of Haematology
- Saudi Commission for Health Specialties (SCFHS)
Research & Publications
Published Papers (Selected)
- Alsharif FZ, et al. Proteomics of Tyrosine Kinase Inhibitor Response in Chronic Myeloid Leukaemia. 2014.
- Alfraih F, Alsharif FZ, et al. CD20 Expression in Adult Acute Lymphoblastic Leukaemia. Blood. 2015;126:3728.
- Alsharif FZ, et al. Plasma Cell Leukaemia — Clinical Experience.
- Alsharif FZ (Co-Editor). Guidelines for Management of Haematological Malignancies, 4th Edition. KFSHRC Riyadh. 2015.
Ongoing Research & Clinical Interests
- Chronic myeloid leukaemia and tyrosine kinase inhibitor resistance
- CD20 expression and targeted therapy in adult ALL
- Bone marrow transplantation outcomes in adult haematological malignancies
- Institutional guideline development for haematological malignancies
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Haematology Consultation | ₹1,000 – ₹2,500 | $12 – $30 |
| Bone Marrow Biopsy & Aspirate | ₹8,000 – ₹25,000 | $100 – $300 |
| Chemotherapy (per cycle) | ₹40,000 – ₹2,00,000 | $480 – $2,400 |
| Autologous Stem Cell Transplant | ₹12,00,000 – ₹18,00,000 | $14,500 – $21,700 |
| Allogeneic Stem Cell Transplant | ₹18,00,000 – ₹30,00,000 | $21,700 – $36,100 |
| CAR-T Cell Therapy | ₹1,50,00,000 – ₹4,00,00,000 | $180,000 – $480,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Fahad Z. Alsharif use in General Haematology treatment?
Dr. Fahad Z. Alsharif uses advanced general haematology technologies including tyrosine kinase inhibitor therapy (imatinib, dasatinib, nilotinib, ponatinib) for chronic myeloid leukaemia, rituximab and CD20-directed therapy, proteasome inhibitors and immunomodulatory drugs for multiple myeloma, minimal residual disease (MRD) monitoring, flow cytometry and molecular diagnostics, and consolidative stem cell transplantation referral pathways. Virtual consultations and remote second opinions are also available to international patients through Cancer Rounds.
2. What conditions does Dr. Fahad Z. Alsharif specialize in treating?
Dr. Fahad Z. Alsharif specialises in General Haematology, treating chronic myeloid leukaemia (CML), acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), multiple myeloma, Hodgkin and non-Hodgkin lymphoma, myelodysplastic syndrome (MDS), plasma cell leukaemia, bone marrow failure syndromes, and post-transplant complications. International patients seeking the best haematology doctor in India or Saudi Arabia benefit from his guideline-driven approach.
3. How do I book an appointment with Dr. Fahad Z. Alsharif?
Appointments with Dr. Fahad Z. Alsharif can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Fahad Z. Alsharif?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Fahad Z. Alsharif, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Fahad Z. Alsharif offer second opinions for General Haematology cases?
Yes. Second opinion consultations for General Haematology cases can be arranged via Cancer Rounds, enabling international patients to review diagnoses, tyrosine kinase inhibitor therapy selection, and transplant candidacy with Dr. Fahad Z. Alsharif.
